Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Go back to Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)| (NASDAQ: PRME) | Delayed: 3.08 +0.13 (4.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.95 | 52 Week High | $21.72 | |||
| Open | $3.00 | 52 Week Low | $18.36 | |||
| Day High | $3.12 | P/E | N/A | |||
| Day Low | $2.97 | EPS | $0.00 | |||
| Volume | 1,976,333 | |||||
